Publications

5808 Results

SWOG S1931 (PROBE trial): Phase III randomized trial of Immune checkpoint inhibitor (ICI) combination regimen with or without Cytoreductive Nephrectomy (CN) in Advanced Renal Cancer

Authors
U Vaishampayan;C Tangen;A Tripathi;B Shuch;S Pal;P Barata;A Tan;P Zuckerman;E Mayerson;P Lara;N Agarwal;N Vogelzang;I Thompson;H Kim
Journal / Conference
Society of Urologic Oncology (Dec 1-3, 2021, Orlando, FL), poster
Year
2021
Research Committee(s)
Genitourinary
Study Number(s)
S1931

Enrollment Characteristics and Outcomes of Hispanic and Black AYA ALL Patients Enrolled on a U.S. Intergroup Clinical Trial: A Comparison of the CALGB 10403 (Alliance) Cohort with U.S. Population-Level Data

Authors
L Muffly;J Yin;S Jacobson;A Advani;S Luger;M Tallman;M Litzow;R Larson;T Keegan;W Stock
Journal / Conference
American Society of Hematology (Dec 11-14, 2021, Atlanta, GA), oral, #337
Year
2021
Research Committee(s)
Leukemia
Study Number(s)
C10403

A041702: A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (= 70 Years of Age) with Chronic Lymphocytic Leukemia (CLL)

Authors
J Woyach;A Ruppert;G Perez;A Booth;D Feldman;E Dib;A Jatoi;J Le-Rademacher;N Heerema;G Lozanski;R Little;B Hill;W Ding;R Stone;S Mandrekar;J Byrd
Journal / Conference
American Society of Hematology (Dec 11-14, 2021, Atlanta, GA), poster, #3728
Year
2021
Research Committee(s)
Leukemia

Long term results of A041202 show continued advantage of ibrutinib-based regimens compared with bendamustine plus rituximab chemoimmunotherapy

Authors
J Woyach;A Ruppert;N Heerema;W Zhao;A Booth;W Ding;N Bartlett;D Brander;P Barr;K Rogers;S Parikh;S Coutre;A Hurria;G Lozanski;S Nattam;R Larson;H Erba;M Litzow;C Owen;J Atkins;J Abramson;R Little;S Smith;R Stone;S Mandrekar;J Byrd
Journal / Conference
American Society of Hematology (Dec 11-14, 2021, Atlanta, GA), oral, #639
Year
2021
Research Committee(s)
Leukemia
Study Number(s)
CTSU/A041202

Extranodal presentation in limited stage DLBCL as a prognostic marker in three sequential SWOG trials S0014, S0313 and S1001 (NCT00005089, NCT00070018, NCT01359592)

Authors
D Stephens;H Li;L Constine;T Fitzgerald;J Leonard;Kahl;J Song;M LeBlanc;S Smith;JW Friedberg;D Persky
Journal / Conference
American Society of Hematology (Dec 11-14, 2021, Atlanta, GA), poster presentation, #1423
Year
2021
Research Committee(s)
Lymphoma
Study Number(s)
S0014, S0313, S1001

Randomized Phase II/III Study of DA-EPOCH-R +/- Venetoclax in Previously Untreated Double Hit Lymphoma: Initial Results from Alliance 051701

Authors
J Abramson;A Ruppert;S Giri;A Hudson;E Hsi;R Little;S Gore;A Vallurupalli;D Landsburg;B Kahl;JW Friedberg;N Bartlett;J Leonard
Journal / Conference
American Society of Hematology (Dec 11-14, 2021, Atlanta, GA), oral, #523
Year
2021
Research Committee(s)
Lymphoma
Study Number(s)
CTSU/A051701

Prediction Of Early Mortality With Non-Intensive Acute Myeloid Leukemia (AML) Therapies: Analysis of 1336 Patients From MRC/NCRI and SWOG

Authors
X Wang;I Thomas;C Ariti;M Dennis;P Mehta;N Russell;M Sydenham;R Hills;A Burnett;S Nand;S Assouline;L Michaelis;H Erba;K Kerr;R Walter;M Othus
Journal / Conference
American Society of Hematology (Dec 11-14, 2021, Atlanta, GA), oral, #220
Year
2021
Research Committee(s)
Leukemia
Study Number(s)
S0432, S0703, S1612

Enhanced immunogenicity within the tumor microenvironment and the circulation of high-risk melanoma patients with unknown primary compared to those whose primary melanoma is known

Authors
A Tarhini;A Tan;I El Naqa;S Lee;F Hodi;L Butterfield;W LaFramboise;W Storkus;J Conejo-Garcia;P Hwu;H Streicher;V Sondak;J Kirkwood
Journal / Conference
Society for Immunotherapy of Cancer’s (SITC) Annual Meeting (Nov 10-14, 2021, Washington, DC), poster
Year
2021
Research Committee(s)
Melanoma
Study Number(s)
CTSU/E1609

Females with high-risk melanoma are more likely to benefit from CTLA4 immune checkpoint inhibition with associated evidence of enhanced immune activation within the TME and the circulation

Authors
M Saad;A Tan;I El Naqa;S Lee;S Hodi;S Butterfield;W LaFramboise;W Storkus;J Conejo-Garcia;P Hwu;H Streicher;V Sondak;J Kirkwood;A Tarhini
Journal / Conference
Society for Immunotherapy of Cancer’s (SITC) Annual Meeting (Nov 10-14, 2021, Washington, DC), poster
Year
2021
Research Committee(s)
Melanoma
Study Number(s)
CTSU/E1609

S1918: A Phase II/III randomized study of R-miniCHOP with or without oral azacitidine (CC-486) in participants age 75 years or older with newly diagnosed diffuse large B cell lymphoma, Grade IIIb Follicular Lymphoma, transformed lymphoma, and high-grade B-cell lymphomas with MYC and BCL2 and/or BCL6 rearrangements

Authors
E Brem;H Li;A Beaven;P Caimi;L Cerchietti;A Alizadeh;R Olin;NL Henry;H Dillon;R Little;C Laubach;M LeBlanc;J Friedberg;S Smith
Journal / Conference
American Society of Hematology (Dec 11-14, 2021, Atlanta, GA), TIPs poster, #3565
Year
2021
Research Committee(s)
Lymphoma
Study Number(s)
S1918